[
  {
    "study_id": "weaver1997",
    "doi": "10.1083/jcb.137.1.231",
    "year": 1997,
    "population": "Previously malignant T4-2 mammary cells; mouse transplantation",
    "contrast": "Integrin-blocking antibody pretreatment versus untreated or control-antibody pretreatment",
    "endpoint_class": "existing_malignant_cell_tumorigenicity",
    "normal_primary_cells_at_start": false,
    "oncogenic_context": "Pre-existing malignant cell line",
    "clinical_incident_cancer_endpoint": false,
    "source_locator": "Results: reversion and reversibility; Table II and tumor formation methods",
    "finding": "Reversion was reversible; treated malignant cells formed fewer tumors in mice.",
    "limit": "Transplanting malignant cells tests tumor-forming capacity, not initial transformation of normal cells."
  },
  {
    "study_id": "levental2009",
    "doi": "10.1016/j.cell.2009.10.027",
    "year": 2009,
    "population": "Oncogene-predisposed mammary mouse model and initiated mammary cells",
    "contrast": "Reduced collagen crosslinking versus control; stiffened versus control matrices",
    "endpoint_class": "oncogene_predisposed_tumor_emergence_and_progression",
    "normal_primary_cells_at_start": false,
    "oncogenic_context": "MMTV-Neu mice; oncogene-initiated cells",
    "clinical_incident_cancer_endpoint": false,
    "source_locator": "Results on LOX inhibition; Figures 3 and 4; invasion experiments, Figures 5 and 6",
    "finding": "Crosslinking inhibition delayed tumors and reduced incidence; stiffness promoted invasion with oncogenic signaling.",
    "limit": "This supplies in vivo emergence evidence, but does not isolate prevention of the earliest transformation event or spontaneous human cancer."
  },
  {
    "study_id": "panciera2020",
    "doi": "10.1038/s41563-020-0615-x",
    "year": 2020,
    "population": "Primary mammary cells and engineered pancreatic mouse models",
    "contrast": "Soft versus stiff matrices; suppression of matrix crosslinking or cell contractility versus control",
    "endpoint_class": "primary_cell_oncogenic_reprogramming_and_tumor_emergence",
    "normal_primary_cells_at_start": true,
    "oncogenic_context": "Introduced or induced oncogenic signaling",
    "clinical_incident_cancer_endpoint": false,
    "source_locator": "Results, Figures 1 and 3; Methods: mouse experiments; Extended Data Figure 3",
    "finding": "Soft environments opposed oncogenic reprogramming; early pathway interventions suppressed neoplastic lesions over the observation period.",
    "limit": "Pathway drugs are not pure mechanical interventions; engineered models and finite follow-up do not establish durable human prevention."
  },
  {
    "study_id": "heenkenda2026",
    "doi": "10.1186/s12964-026-03138-x",
    "year": 2026,
    "population": "Human breast cohorts and platelet co-cultures",
    "contrast": "Dense versus nondense tissue; exploratory aspirin intervention; tunable culture stiffness",
    "endpoint_class": "human_biomarkers_and_cell_response",
    "normal_primary_cells_at_start": false,
    "oncogenic_context": "Human tissue cohorts and breast-cancer-cell co-cultures",
    "clinical_incident_cancer_endpoint": false,
    "source_locator": "Materials and methods: Subjects; Results: ASA and platelet experiments; Figures 5 and 6",
    "finding": "The report connects density-associated proteins with platelet responses to stiffness.",
    "limit": "The human intervention reports biomarkers, not incident cancer or restoration of measured tissue mechanics."
  }
]